Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Atrium Therapeutics (RNA) will present nonclinical findings showing that a mouse version of ATR 1072 improved features of PRKAG2 syndrome.
In a new mouse model, a single dose of mATR 1072 reversed cardiac glycogen accumulation, or stored sugar buildup in the heart, and improved heart muscle thickening and electrocardiogram (ECG) measures of electrical activity. Treatment began after disease features had been established for three weeks. The mouse surrogate targeted disease-causing variant PRKAG2 messenger RNA in the heart; these results are from mice, not patients receiving ATR 1072.
The poster presentation is scheduled for November 6, 2026, at 5:30 p.m. CT during HCMS at the American Heart Association Scientific Sessions in Chicago. Atrium expects initial proof-of-concept data from its ongoing Phase 1/2 Corventis trial in the second half of 2027.
Atrium Therapeutics (Nasdaq: RNA) has dosed the first patient in its Phase 1/2 Corventis trial evaluating ATR 1072 for PRKAG2 syndrome. The global trial will evaluate the investigational therapy in approximately 37 participants. Atrium expects initial proof-of-concept data in the second half of 2027.
PRKAG2 syndrome is a rare, progressive genetic heart muscle disease that can lead to heart failure and sudden cardiac death. Mutations in PRKAG2 cause overactivity of AMP-activated protein kinase, or AMPK, resulting in glycogen accumulation in heart muscle. ATR 1072 combines an antibody with an RNA-targeting molecule and is designed to silence mutant PRKAG2 messenger RNA, normalize AMPK overactivation and improve heart function. These are intended effects, not reported clinical results.
Atrium Therapeutics (RNA) awarded stock options and restricted stock units to one newly hired non-executive employee as an employment inducement. The grants comprise options to purchase 9,500 shares at $7.98 per share, the closing share price on the grant's effective date, and restricted stock units covering 4,750 shares.
Both awards vest 25% on the first grant anniversary. The remaining options vest in 36 substantially equal monthly installments; the remaining restricted stock units vest in three substantially equal annual installments. Vesting requires continued service through each applicable date. The independent Human Capital Management Committee approved the awards under the 2026 Employment Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Summary not available.
Atrium Therapeutics (RNA) entered into a securities purchase agreement for a private placement expected to raise approximately $50 million in gross proceeds.
The financing comprises 5,170,384 common shares at $7.93 each and pre-funded warrants to purchase up to 1,134,930 shares at $7.929 per warrant, with a $0.001 exercise price. Closing is expected on or about October 9, 2026, subject to customary closing conditions. Atrium intends to fund development of its two lead product candidates and other research programs, alongside working capital and general corporate purposes. It estimates the net proceeds, combined with existing cash, cash equivalents and investments, will fund operations through 2028.
Atrium Therapeutics (RNA) granted equity inducement awards on September 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan.
The employee received non-qualified stock options for 13,500 shares at an exercise price of $8.95 per share, with 25% vesting on the first anniversary and the remainder vesting in 36 monthly installments thereafter, subject to continued service. The employee also received restricted stock units covering 6,750 shares, with 25% vesting on the first anniversary and the remainder vesting in three annual installments, also subject to continued service. The awards were approved by the Human Capital Management Committee of the board, in accordance with Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics (RNA) will participate in three healthcare investor conferences in September 2026. The company highlights recent milestones, including FDA clearance of its IND for ATR-1072 for PRKAG2 syndrome, a No Objection Letter from Health Canada, initiation of the Corventis™ Phase 1/2 trial, and reporting of second quarter 2026 results.
Conference schedule: Wells Fargo 21st Annual Healthcare Conference, fireside chat on September 8, 2026 at 8:00 a.m. ET in Boston, MA; 2026 Cantor Global Healthcare Conference, fireside chat on September 9, 2026 at 11:30 a.m. ET in New York, NY; Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026 in New York, NY. Webcast details and replays will be available for at least 30 days on Atrium’s investor relations website.
Atrium Therapeutics (Nasdaq: RNA) granted equity inducement awards on August 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan. The package includes non-qualified options for 11,000 shares at an exercise price of $13.48 and 5,500 restricted stock units, with multi-year time-based vesting, approved by the board’s independent Human Capital Management Committee under Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics (Nasdaq: RNA) reported second quarter 2026 results and advanced its precision cardiology pipeline. FDA cleared the IND for ATR 1072, and Health Canada issued a No Objection Letter, enabling the Corventis Phase 1/2 trial in PRKAG2 syndrome, which is planned to enroll about 37 participants in two parts. Atrium also earned a second $15 million milestone under its global cardiovascular collaboration with Bristol Myers Squibb, to be recognized in third quarter 2026.
For Q2 2026, collaboration revenue was $3.0 million. R&D expenses were $15.3 million and G&A expenses were $10.3 million, leading to a net loss of $20.2 million. As of June 30, 2026, cash, cash equivalents and short‑term investments totaled $263.9 million. According to Atrium, this, including the BMS milestone, is expected to fund operations through mid‑2028.
Atrium Therapeutics (Nasdaq: RNA) announced it has earned a $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) after delivering a second lead RNA-based compound for an undisclosed cardiovascular indication under their global licensing and research collaboration.
According to Atrium Therapeutics, the BMS agreement includes eligibility for up to approximately $1.35 billion in research and development milestones, up to approximately $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities arising from the collaboration. Atrium is also advancing ATR 1072 for PRKAG2 syndrome into the Corventis Phase 1/2 trial following recent FDA IND clearance, and maintains a pipeline including ATR 1086 for PLN cardiomyopathy and two additional rare cardiomyopathy programs.